ADUC
Live / Registered — Registered (as of 23 Dec 2025)
What this means for you
Registered since 23 Dec 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79429112
- Registration number
- 8073026
- Mark type
- Stylized text
- Filed
- 20 May 2025
- Published for opposition
- 04 Nov 2025
- Registered
- 23 Dec 2025
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; veterinary preparations for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; vaccines for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; therapeutic medicines for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases; therapeutic antibodies for the treatment and prevention of cardiovascular disease, cerebrovascular disease, dyslipidemia, thrombosis, hyperphosphatemia, hypertension, diabetes, cancer, oncological disease, leukemia, metastasis, immunological disorder, autoimmune disease, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, kidney disease, skin disease, osteoporosis, ophthalmic disorders, sensory organ disorders, aging-related diseases.
Owner
- KOWA COMPANY, LTD., JP
- KOWA COMPANY, LTD., JP
- KOWA COMPANY, LTD., JP
Prosecution history
- 22 Jan 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 23 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 04 Nov 2025 — PUBLISHED FOR OPPOSITION
- 29 Oct 2025 — NOTICE OF PUBLICATION
- 02 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Oct 2025 — ASSIGNED TO EXAMINER
- 14 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 14 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 11 Aug 2025 — LIMITATION FROM ORIGINAL APPLICATION ENTERED
- 31 Jul 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB